Gallagher, Julia
Mamikonyan, Eugenia
Xie, Sharon X.
Tran, Baochan
Shaw, Sarah
Weintraub, Daniel
Funding for this research was provided by:
National Institute on Aging (U19 AG062418, U19 AG062418, U19 AG062418, U19 AG062418, U19 AG062418, U19 AG062418)
Article History
Received: 26 April 2023
Accepted: 16 September 2023
First Online: 27 September 2023
Competing interests
: DW: In the past year Dr. Weintraub has received research funding or support from Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Therapeutic Research Initiative (ATRI), Alzheimer's Disease Cooperative Study (ADCS), International Parkinson and Movement Disorder Society (IPMDS), National Institute on Health (NIH), Parkinson's Foundation; U.S. Department of Veterans Affairs and Acadia Pharmaceuticals; honoraria for consultancy from Acadia Pharmaceuticals, Alkahest, Aptinyx, Cerevel Therapeutics, CHDI Foundation, Clintrex LLC (Otsuka), EcoRl Capital, Eisai, Perring, Gray Matter Technologies, Great Lake Neurotechnologies, Intra-Cellular Therapies, Janssen, Merck, Sage, Scion and Signant Health; and license fee payments from the University of Pennsylvania for the QUIP and QUIP-RS. SX: Dr. Xie receives research funding from U.S. National Institute of Health; serves as a consultant to Roche on a cancer clinical trial. Authors JG, EM, SS, and BT declare no financial or non-financial competing interests.